IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pau et al.

Serial No.: 09/722,867

Filed: November 27, 2000

For: PRODUCTION OF VACCINES

Examiner: M. Hill

Group Art Unit: 1648

Attorney Docket No.: 2578-4626US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 27, 2005
Date

Signature

Betty Vowles
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of U.S. patents are not being submitted pursuant to M.P.E.P. 609 III A(2). Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2) except as noted below.

U.S. Patent Documents

U.S. Patent No.	Publication Date	Patentee
US-4,703,008	10-27-1987	Lin
US- 4,835,260	05-30-1989	Shoemaker
US- 5,047,335	09-10-1991	Paulson et al.

US- 5,441,868	08-15-1995	Lin
US- 5,457,089	10-10-1995	Fibi et al.
US- 5,494,790	02-27-1996	Sasaki et al.
US- 5,767,078	06-16-1998	Johnson et al.
US- 5,773,569	06-30-1998	Wrighton et al.
US- 5,789,247	08-04-1998	Ballay et al.
US- 5,830,851	11-03-1998	Wrighton et al.
US- 5,835,382	11-10-1998	Wilson et al.
US- 5,856,298	01-05-1999	Strickland
US- 5,994,128	11-30-1999	Fallaux et al.
US- 6,033,908	03-01-2000	Bout et al.
US- 6,492,169 B1	12-10-2002	Vogels et al.
US- 6,558,948	05-06-2003	Kochanek et al.
US- 6,653,101 B1	11-25-2003	Cockett et al.
US- 6,855,544	02-15-2005	Hateboer et al.
US- 2002/116723 A1	08-22-2002	Grigliatti et al.
US- 2003/0087437 A1	05-08-2003	Asada et al.
US- 2003/0092160	05-15-2003	Bout et al.

Foreign Patent Documents

Document No.	Publication Date	Patentee
WO 93/03163	02-18-1993	Fond Nat Transfusion
WO 95/05465	02-23-1995	Amgen Inc.
WO 95/29994	11-09-1995	Univ Michigan
WO 97/00326	01-03-1997	Univ Leiden
WO 98/18926	05-07-1998	G.D. Searle & Co.
WO 98/39411	09-11-1998	Baxter International Inc.
WO 98/44141	10-08-1998	The University of British Columbia

WO 99/05268	02-04-1999	Boehringer Mannheim GMBH
WO 00/61164	10-19-2000	Kenneth S. Warren Laboratories
WO 00/63403	10-26-2000	Introgene B.V.
WO 01/38362 A2	05-31-2001	Crucell Holland B.V.
WO 02/053580	07-11-2002	The Kenneth S. Warren Institute, Inc.
WO 03/038100 A1	05-08-2003	Crucell Holland B.V.
WO 03/048197 A1	06-12-2003	Crucell Holland B.V.
WO 03/048348 A2	06-12-2003	Crucell Holland B.V.
WO 03/051927	06-26-2003	Crucell Holland B.V.
WO 2004/003176	01-08-2004	The Kenneth S. Warren Institute, Inc.
WO 2004/099396	11-18-2004	Crucell Holland B.V.
EP 0 185 573	06-25-1995	Univ Michigan
EP 0 411 678	02-06-1991	Genetics Institute, Inc.

Other Documents

BOUT et al., "Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors," Cancer Gene Therapy, 1996, pp. S24, Vol. 3, No. 6.

BOUT et al., "Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER.C6," Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.

BOUTL et al., "A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, Vol. 4, No. 6.

CARROLL et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, Virus Research, Sep. 1985, pp. 165-79, Vol. 3, No. 2.

CRONAN, Abstract, Biotination of Proteins in-vivo a post-translational modification to label purify and study proteins, Journal of Biological Chemistry, June 25, 1990, pp. 10327-33, Vol. 265, No. 18.

ENDO et al., Growth of Influenza A Virus in Primary, Differentiated Epithelial Cells Derived from Adenoids, Journal of Virology, Mar. 1996, pp. 2055-58, Vol. 70, No. 3.

FALLAUX et al, "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses," Human Gene Therapy, Sept. 1, 1998, Vol. 9, No. 1, pp. 1909-1917. Abstract.

GHOSH-CHOUDHURY et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-39, Vol. 6, No. 6.

GRABENHORST et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)GlcNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially attached to the Gal(beta-1-4)GlcNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, Eur. J. Biochem, 1995, pp. 718-25, Vol. 232, No. 3, Berlin, Germany.

GRAND et al., "Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells," Eur Mol Biol Organ J. 1986, 5 (6) 1253-1260. Abstract.

GRAND et al., "The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression," Virology, 1995, Vol. 210, No. 2, pp. 323-334. Abstract.

HOLLISTER et al., Stable expression of mammalian beta1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells, Glycobiology, 1998, pp. 473-80, Vol. 8, No. 5, IRL Press, United Kingdom.

JENKINS et al., Getting the glycosylation right: Implications for the biotechnology industry, Nature Biotechnology, August 1996, pp. 975-81, Vol. 14, No. 8, Nature Publishing, US.

LOUIS et al., Cloning and Sequencing of the Cellular--Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, Virology, 1997, pp. 423-29, Vol. 233.

MERTEN et al., Production of Influenza Virus in Cell Cultures for Vaccine Preparation, Exp Med Biol., 1996, pp. 141-51, Vol. 397.

MINCH et al., Tissue Plasminogen Activator Coexpressed in Chinese Hamster Ovary Cells with alpha(2,6)-Sialyltransferase Contains NeuAc-alpha(2,6)Gal-beta(1,4)Glc-N-AcR Linkages, Biotechnol. Prog., 1995, pp. 348-51, Vol. 11, No. 3.

NCBI Entrez Nucleotide accession number NC_002018.

NCBI Entrez Nucleotide accession number U38242.

NCBI Entrez Nucleotide accession number X02996 J01967 J01968 J01970 J01971 J01972 J01974 J01976 J01977 J01978 J01979 K00515 V00025 V00026 V00027 V00029.

PACITTI et al., Inhibition of Reovirus Type 3 Binding to Host Cells by Sialylated Glycoproteins Is Mediated through the Viral Attachment Protein, Journal of Virology, May 1987, pp. 1407-15, Vol. 61, No. 5, American Society for Microbiology.

PAU et al., Abstract, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, Mar. 21, 2001, pp. 2716-21, Vol. 19, No. 17-19.

PAUL et al., Increased Viral Titer Through Concentration of Viral Harvests from Retroviral Packaging Lines, Human Gene Therapy, 1993, pp. 609-15, Vol. 4.

PAZUR et al., Abstract, Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies, Journal of Protein Chemistry, November 2000, pp. 631-35, Vol. 19, No. 8.

REINA et al., Comparison of Madin-Darby Canine Kidney cells (MDCK) with a Green Monkey Continuous Cell Line (Vero) and Human Lung Embryonated Cells (MRC-5) in the Isolation of Influenza A Virus from Nasopharyngeal Aspirates by Shell Vial Culture, Journal of Clinical Microbiology, July 1997, pp. 1900-01, Vol. 35, No. 7.

SCHIEDNER et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, 2000, Hum. Gene Ther. 11, 2105-2116.

SETOGUCHI et al., "Stimulation of Erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the humanerythropoietin gene to experimental animals using an adenovirus vector," Blood, November 1, 1994, pp. 2946-53, Vol. 84, No. 9.

STOCKWELL et al., High-throughput screening of small molecules in Miniaturized Mammalian Cell-based Assays involving Post-translational Modifications, Chemistry and Biology, February 1999, pp. 71-83, Vol. 6, No. 2.

WEIKERT et al., Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins, Nature Biotechnology, November 1999, pp. 1116-21, Vol. 17, No. 11, Nature Pub. Co., New York, NY, US.

YU et al., "Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A," Cancer Res., 1993, 53 (4) 891-8. Abstract.

ZHANG et al., Stable expression of human alpha-2,6-sialyltransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity, BBA - General Subjects, 1998, pp. 441-52, Vol. 1425, No. 3, Elsevier Science Publishers, NL.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:
Serial No.: 09/722,867
Filed: November 27, 2000
For: PRODUCTION OF VACCINES, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Dock et No.:	2578-4240US
Serial No.:	09/449,854
Filing Date:	11/26/1999
Title:	PRODUCTION OF VACCINES

Attorney Docket No.:	2578-4192.1US
Serial No.:	09/657,492
Filing Date:	9/8/2000
Title:	MODIFIED ADENOVIRAL VECTORS FOR USE IN GENE THERAPY
Attorney Docket No.:	2578-4843US
Serial No.:	09/843,894
Filing Date:	4/27/2001
Title:	AAV VECTOR PRODUCTION
Attorney Docket No.:	2578-4451.1US
Serial No.:	10/196,688
Filing Date:	7/15/2002
Title:	ADENO-ASSOCIATED VIRUS AND ADENOVIRUS CHIMERIC RECOMBINANT VIRUSES USEFUL FOR THE INTEGRATION OF FOREIGN GENETIC INFORMATION INTO CHROMOSOMAL DNA OF TARGET CELLS
Attorney Docket No.:	2578-4038.2US
Serial No.:	10/234,007
Filing Date:	9/3/2002
Title:	RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL
Attorney Docket No.:	2578-6448US
Serial No.:	10/497,832
Filing Date:	1/10/2005
Title:	PRODUCTION OF VIRUSES, VIRAL ISOLATES AND VACCINES
Attorney Docket No.:	2578-6158US
Serial No.:	10/698,086
Filing Date:	10/30/2003
Title:	METHODS FOR THE IDENTIFICATION OF ANTIVIRAL COMPOUNDS
Attorney Docket No.:	2578-3982.3US
Serial No.:	10/783,510
Filing Date:	2/20/2004
Title:	MEANS AND METHODS FOR FIBROBLAST-LIKE OR MACROPHAGE-LIKE CELL TRANSDUCTION

Attorney Docket No.:	2578-4038.3US
Serial No.:	10/790,562
Filing Date:	3/1/2004
Title:	RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL
Attorney Docket No.:	2578-6448.1US
Serial No.:	11/026,518
Filing Date:	12/30/2004
Title:	OVEREXPRESSION OF ENZYMES INVOLVED IN POST-TRANSLATIONAL PROTEIN MODIFICATIONS IN HUMAN CELLS
Attorney Docket No.:	2578-6964US
Serial No.:	11/102,073
Filing Date:	4/8/2005
Title:	COMPOSITIONS OF ERYTHROPOIETIN ISOFORMS COMPRISING LEWIS-X STRUCTURES AND HIGH SIALIC ACID CONTENT
Attorney Docket No.:	2578-6845US
Serial No.:	11/105,725
Filing Date:	4/14/2005
Title:	NEW SETTINGS FOR RECOMBINANT ADENOVIRAL-BASED VACCINES
Attorney Docket No.:	2578-6827US
Serial No.:	11/110,517
Filing Date:	4/20/2005
Title:	VACCINES AGAINST WEST NILE VIRUS
Attorney Docket No.:	2578-6979US
Serial No.:	11/143,986
Filing Date:	6/2/2005
Title:	RECOMBINANT VIRAL-BASED MALARIA VACCINES
Attorney Docket No.:	2578-6691US
Serial No.:	60/619,056
Filing Date:	10/14/2004
Title:	MALARIA PRIME/BOOST VACCINES

Attorney Docket No.:	2578-7192US
Serial No.:	60/683,266
Filing Date:	5/19/2005
Title:	METHODS FOR THE PRODUCTION OF A WHOLE-INACTIVATED WEST NILE VIRUS VACCINE

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits. The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 26, 2005
ACT/bv

Enclosures: Form PTO/SB/08
Check in the amount of $180
Document in ProLaw

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	09/722,867
Filing Date	November 27, 2000
First Named Inventor	Pau et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-4626US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	Document Number: Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,703,008	10-27-1987	Lin	
		US- 4,835,260	05-30-1989	Shoemaker	
		US- 5,047,335	09-10-1991	Paulson et al.	
		US- 5,441,868	08-15-1995	Lin	
		US- 5,457,089	10-10-1995	Fibi et al.	
		US- 5,494,790	02-27-1996	Sasaki et al.	
		US- 5,767,078	06-16-1998	Johnson et al.	
		US- 5,773,569	06-30-1998	Wrighton et al.	
		US- 5,789,247	08-04-1998	Ballay et al.	
		US- 5,830,851	11-03-1998	Wrighton et al.	
		US- 5,835,382	11-10-1998	Wilson et al.	
		US- 5,856,298	01-05-1999	Strickland	
		US- 5,994,128	11-30-1999	Fallaux et al.	
		US- 6,033,908	03-01-2000	Bout et al.	
		US- 6,492,169 B1	12-10-2002	Vogels et al.	
		US- 6,558,948	05-06-2003	Kochanek et al.	
		US- 6,653,101 B1	11-25-2003	Cockett et al.	
		US- 6,855,544	02-15-2005	Hateboer et al.	
		US- 2002/116723 A1	08-22-2002	Grigliatti et al.	
		US- 2003/0087437 A1	05-08-2003	Asada et al.	
		US- 2003/0092160	05-15-2003	Bout et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 93/03163	02-18-1993	Fond Nat Transfusion		
		WO 95/05465	02-23-1995	Amgen Inc.		
		WO 95/29994	11-09-1995	Univ Michigan		
		WO 97/00326	01-03-1997	Univ Leiden		
		WO 98/18926	05-07-1998	G.D. Searle & Co.		
		WO 98/39411	09-11-1998	Baxter International Inc.		
		WO 98/44141	10-08-1998	The University of British Columbia		
		WO 99/05268	02-04-1999	Boehringer Mannheim GMBH		
		WO 00/61164	10-19-2000	Kenneth S. Warren Laboratories		
		WO 00/63403	10-26-2000	Introgene B.V.		
		WO 01/38362 A2	05-31-2001	Crucell Holland B.V.		
		WO 02/053580	07-11-2002	The Kenneth S. Warren Institute, Inc.		
		WO 03/038100 A1	05-08-2003	Crucell Holland B.V.		
		WO 03/048197 A1	06-12-2003	Crucell Holland B.V.		
		WO 03/048348 A2	06-12-2003	Crucell Holland B.V.		
		WO 03/051927	06-26-2003	Crucell Holland B.V.		
		WO 2004/003176	01-08-2004	The Kenneth S. Warren Institute, Inc.		
		WO 2004/099396	11-18-2004	Crucell Holland B.V.		
		EP 0 185 573	06-25-1995	Univ Michigan		
		EP 0 411 678	02-06-1991	Genetics Institute, Inc.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223131450.

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	09/722,867
Filing Date	November 27, 2000
First Named Inventor	Pau et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-4626US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		BOUT et al., "Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors," Cancer Gene Therapy, 1996, pp. S24, Vol. 3, No. 6.	
		BOUT et al., "Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER.C6," Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.	
		BOUTL et al., "A novel packaging cell line (PER.C6) for efficient production of RCAfree batches of E1-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, Vol. 4, No. 6.	
		CARROLL et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, Virus Research, Sep. 1985, pp. 165-79, Vol. 3, No. 2.	
		CRONAN, Abstract, Biotination of Proteins in-vivo a post-translational modification to label purify and study proteins, Journal of Biological Chemistry, June 25, 1990, pp. 10327-33, Vol. 265, No. 18.	
		ENDO et al., Growth of Influenza A Virus in Primary, Differentiated Epithelial Cells Derived from Adenoids, Journal of Virology, Mar. 1996, pp. 2055-58, Vol. 70, No. 3.	
		FALLAUX et al, "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses," Human Gene Therapy, Sept. 1, 1998, Vol. 9, No. 1, pp. 19091917. Abstract.	
		GHOSH-CHOUDHURY et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 173339, Vol. 6, No. 6.	
		GRABENHORST et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)GlcNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially atached to the Gal(beta-1-4)GlcNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant betatrace protein, Eur. J. Biochem, 1995, pp. 718-25, Vol. 232, No. 3, Berlin, Germany.	
		GRAND et al., "Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells," Eur Mol Biol Organ J. 1986, 5 (6) 1253-1260. Abstract.	
		GRAND et al., "The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression," Virology, 1995, Vol. 210, No. 2, pp. 323-334. Abstract.	
		HOLLISTER et al., Stable expression of mammalian beta1,4galactosyltransferase extends the N-glycosylation pathway in insect cells, Glycobiology, 1998, pp. 473-80, Vol. 8, No. 5, IRL Press, United Kingdom.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number (optional).[2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	09/722,867
Filing Date	November 27, 2000
First Named Inventor	Pau et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-4626US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		JENKINS et al., Getting the glycosylation right: Implications for the biotechnology industry, Nature Biotechnology, August 1996, pp. 975-81, Vol. 14, No. 8, Nature Publishing, US.	
		LOUIS et al., Cloning and Sequencing of the Cellular-Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, Virology, 1997, pp. 423-29, Vol. 233.	
		MERTEN et al., Production of Influenza Virus in Cell Cultures for Vaccine Preparation, Exp Med Biol., 1996, pp. 141-51, Vol. 397.	
		MINCH et al., Tissue Plasminogen Activator Coexpressed in Chinese Hamster Ovary Cells with alpha(2,6)-Sialyltransferase Contains NeuAc-alpha(2,6)Gal-beta(1,4)Glc-N-AcR Linkages, Biotechnol. Prog., 1995, pp. 348-51, Vol. 11, No. 3.	
		NCBI Entrez Nucleotide accession number NC_002018.	
		NCBI Entrez Nucleotide accession number U38242.	
		NCBI Entrez Nucleotide accession number X02996 J01967 J01968 J01970 J01971 J01972 J01974 J01976 J01977 J01978 J01979 K00515 V00025 V00026 V00027 V00029.	
		PACITTI et al., Inhibition of Reovirus Type 3 Binding to Host Cells by Sialylated Glycoproteins Is Mediated through the Viral Attachment Protein, Journal of Virology, May 1987, pp. 1407-15, Vol. 61, No. 5, American Society for Microbiology.	
		PAU et al., Abstract, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, Mar. 21, 2001, pp. 2716-21, Vol. 19, No. 17-19.	
		PAUL et al., Increased Viral Titer Through Concentration of Viral Harvests from Retroviral Packaging Lines, Human Gene Therapy, 1993, pp. 609-15, Vol. 4.	
		PAZUR et al., Abstract, Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies, Journal of Protein Chemistry, November 2000, pp. 631-35, Vol. 19, No. 8.	
		REINA et al., Comparison of Madin-Darby Canine Kidney cells (MDCK) with a Green Monkey Continuous Cell Line (Vero) and Human Lung Embryonated Cells (MRG5) in the Isolation of Influenza A Virus from Nasopharyngeal Aspirates by Shell Vial Culture, Journal of Clinical Microbiology, July 1997, pp. 1900-01, Vol. 35, No. 7.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	09/722,867
Filing Date	November 27, 2000
First Named Inventor	Pau et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-4626US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T[2]
		SCHIEDNER et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, 2000, Hum. Gene Ther. 11, 21052116.	
		SETOGUCHI et al., "Stimulation of Erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the humanerythropoietin gene to experimental animals using an adenovirus vector," Blood, November 1, 1994, pp. 29463, Vol. 84, No. 9.	
		STOCKWELL et al., High-throughput screening of small molecules in Miniaturized Mammalian Cell-based Assays involving Post-translational Modifications, Chemistry and Biology, February 1999, pp. 7183, Vol. 6, No. 2.	
		WEIKERT et al., Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins, Nature Biotechnology, November 1999, pp. 1116-21, Vol. 17, No. 11, Nature Pub. Co., New York, NY, US.	
		YU et al., "Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A," Cancer Res., 1993, 53 (4) 891-8. Abstract.	
		ZHANG et al., Stable expression of human alpha2,6-sialyltransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity, BBA- General Subjects, 1998, pp. 441-52, Vol. 1425, No. 3, Elsevier Science Publishers, NL.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.